- Investors were not impressed with data presented after the closing bell yesterday on Cue Biopharma's (CUE -26.5%) combination treatment for head and neck cancer and the stock is taking a beating today.
- Data showed that CUE-101 in combination with Keytruda (pembrolizumab) led to partial responses in two out of four patients, though one of those responses was unconfirmed.
- Before today's drop, Cue shares were down more than 6% year to date.
- CUE-101 is also under evaluation as a monotherapy for head and neck cancer.
Cue data on head and neck cancer candidate doesn't impress investors; shares down 26%
Recommended For You
More Trending News
About CUE Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CUE | - | - |
Cue Biopharma, Inc. |